Back to News
Market Impact: 0.12
Sun Pharma Launches Taro-Methylphenidate ER, Generic Alternative To Concerta
Source: Nasdaq
Healthcare & BiotechProduct Launches
Sun Pharmaceutical Industries announced commercial availability of Taro-Methylphenidate ER in Ontario and Quebec, Canada. The product launch expands patient access in two major Canadian provinces, though the article provides no sales, pricing, or revenue-impact estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?